LivaNova beats estimates in Q1 as FDA approval for sleep apnea device bolsters outlook
LivaNova (NASDAQ:LIVN) delivered a robust first-quarter performance for 2026, characterized by double-digit revenue growth and a major regulatory win in the sleep apnea market.










